Metformin

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instanceOf gptkb:drug
biguanide
gptkbp:approvedInUS 1994
gptkbp:ATCCode A10BA02
gptkbp:bioavailability 50–60%
gptkbp:brand gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
gptkbp:CASNumber 657-24-9
gptkbp:category antidiabetic medication
gptkbp:chemicalFormula C4H11N5
gptkbp:contraindication liver failure
severe kidney disease
gptkbp:discoveredBy gptkb:James_Bell
gptkb:Emile_Werner
gptkbp:discoveredIn 1922
gptkbp:drugClass antihyperglycemic agent
gptkbp:effectOnWeight weight neutral or modest loss
gptkbp:eliminationHalfLife 4-8.7 hours
gptkbp:excretion renal
gptkbp:firstSynthesized 1922
gptkbp:form gptkb:tablet
oral solution
extended-release tablet
gptkbp:foundIn gptkb:WHO_Model_List_of_Essential_Medicines
https://www.w3.org/2000/01/rdf-schema#label Metformin
gptkbp:legalStatus prescription only
gptkbp:marketedAs 1957
gptkbp:mechanismOfAction decreases hepatic glucose production
increases insulin sensitivity
gptkbp:meltingPoint 223–226 °C
gptkbp:metabolism not metabolized
gptkbp:molecularWeight 129.164 g/mol
gptkbp:origin derived from Galega officinalis
gptkbp:pregnancyCategory B
gptkbp:prescribes adults
children over 10 years
gptkbp:prescriptionStatus Rx only
gptkbp:proteinBinding negligible
gptkbp:riskOfHypoglycemia low
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gastrointestinal upset
lactic acidosis
gptkbp:usedFor gptkb:polycystic_ovary_syndrome
gptkb:type_2_diabetes
gptkbp:WHOModelListOfEssentialMedicines true
gptkbp:bfsParent gptkb:DB00740
gptkb:DB00783
gptkb:DB00303
gptkb:DB00170
gptkb:DB00162
gptkbp:bfsLayer 6